Incidence of SARS-CoV-2 Infection Among Patients Undergoing
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
The interactions between cancer and susceptibility to COVID-19 are poorly understood. Early reports suggested a higher COVID-19 risk in patients with cancer not specifically selected for recent anticancer treatment but data on SARS-CoV-2 transmission among patients undergoing antitumor treatment are lacking.

To calculate the rate of SARS-CoV-2 infection among patients receiving antitumor treatment aggregate data were registered on all patients who received at least 1 course of an active anticancer treatment. Individual data were collected for those developing COVID-19 as assessed through PCR test from a nasopharyngeal.

Results:
Of 59 989 patients receiving antitumor treatment, 406 developed COVID-19 with a positive nasopharyngeal PCR test result.The median age of infected patients was 68.

Most were symptomatic (n = 339), and 314 required hospitalization. Lung cancer was the most common tumor (n = 91), and chemotherapy the most represented antitumor treatment (n = 252). The infection rate was higher compared with the general Italian population during the same time period and varied between different geographical areas.

Conclusion:
They concluded that the low probability of SARSCoV-2 infection among these patients supports the continuation of most oncologic treatments in the adjuvant and metastatic setting. Based on the present data, delaying active antitumor treatment to avoid SARS-CoV-2 transmission should not be routinely recommended.

Source:
https://jamanetwork.com/journals/jamaoncology/fullarticle/2773836?alert=article
Dr. T●●●●z H●●●●●●i and 1 others like this
Like
Comment
Share